Renal Cancer - Results from #2740

The SLC Family Are Candidate Diagnostic and Prognostic Biomarkers in Clear Cell Renal Cell Carcinoma. June 5, 2020

Metastasectomy in patients with renal cell carcinoma: when and how? June 4, 2020

Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. June 4, 2020

Expression and clinical value of SALL4 in renal cell carcinomas. June 4, 2020

Circular RNA hsa_circ_0054537 sponges miR-130a-3p to promote the progression of Renal Cell Carcinoma through regulating cMet pathway. June 4, 2020

Obesity induces limited changes to systemic and local immune profiles in treatment-naive human clear cell renal cell carcinoma. June 3, 2020

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. June 3, 2020

Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. June 2, 2020

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. June 2, 2020

Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. June 1, 2020

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma The SAVOIR Phase 3 Randomized Clinical Trial May 29, 2020

Comprehensive analysis of the HOXA gene family identifies HOXA13 as a novel oncogenic gene in kidney renal clear cell carcinoma. May 29, 2020

New Treatments in Renal Cancer: The AhR Ligands. May 29, 2020

Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma. May 28, 2020

Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report. May 28, 2020

Assessing Genomic Copy Number Alterations as Best Practice for Renal Cell Neoplasia: An Evidence-Based Review from the Cancer Genomics Consortium Workgroup. May 28, 2020

Partial vs. radical nephrectomy and the risk of all-cause mortality, cardiovascular, and nephrological outcomes. May 28, 2020

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). May 27, 2020

Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. May 27, 2020

Molecular targeting of renal cell carcinoma by an oral combination. May 27, 2020

Page 138 of 456